Product Details
Synonyms
B7-H6, NCR3LG1, B7 Homolog 6
Source
Biotinylated Human B7-H6, Fc,Avitag (B76-H82Wb) is expressed from human 293 cells (HEK293). It contains AA Asp 25 - Ser 262 (Accession # Q68D85-1).
Predicted N-terminus: Asp 25
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 54.8 kDa. The protein migrates as 66-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Biotinylated Human B7-H6, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA

Immobilized Human NKp30, Fc Tag (Cat. No. NC3-H5259) at 10 μg/mL (100 μL/well) can bind Biotinylated Human B7-H6, Fc,Avitag (Cat. No. B76-H82Wb) with a linear range of 0.6-10 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.
Recent Advances
メールアドレス
order.jp@acrobiosystems.comお問い合わせ
グローバル:+1 800-810-0816(Toll Free)



















